Abstract:
The subject disclosure relates to methods of contraception, and compositions useful in such methods. Disclosed are methods in which one or more sperm surface proteins are administered to a mammal, the administration being effective in stimulating an immune response whereby antibody which binds to the sperm surface protein is produced in a titer sufficient to prevent or substantially reduce the rate of sperm-egg fusion. Antigenic sperm surface protein peptides are also useful for this purpose.
Abstract:
Molecular complexes for targeting a gene encoding a secretory protein to a specific cell in vivo and obtaining secretion of the protein by the targeted cell are disclosed. An expressible gene encoding a desired secretory protein is complexed to a conjugate of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of ligands by endocytosis. An example is the asialoglycoprotein receptor of hepatocytes. The gene-binding agent is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function within a cell. The molecular complex is stable and soluble in physiological fluids and can be used in gene therapy to selectively transfect cells in vivo to provide for production and secretion of a desired secretory protein.
Abstract:
A method for screening for Lyme borreliosis and other infectious diseases early in the course of the disease are disclosed. It has been found that there is a dramatic difference in surface binding of cultured infectious agents to naturally occurring polymorphonuclear leukocytes (PMNs) (e.g., neutrophils) between infected and noninfected animals, which may be present early in the course of the disease, before measurable antibody response. This binding response can be rapidly and accurately distinguished and quantitated using various detection techniques. The method involves visualizing the surface binding of the cultured infectious agent to naturally-occurring PMN to detect the infection.
Abstract:
Molecular complexes for targeting a gene encoding a microsomal enzyme selective for delivery to a cell in vivo or in vitro obtaining production of the enzyme within the targeted cell are disclosed. An expressible gene encoding a desired enzyme is complexed to a conjugate of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of ligands by endocytosis. An example is the asialoglycoprotein receptor of hepatocytes. The gene-binding agent is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function whithin a cell. The molecular complex is stable and soluble in physiological fluids and can be used in antisense gene therapy to selectively transfect cells in vivo to treat inherited or acquired deficiencies in cellular microsomal enzymes.
Abstract:
Molecular complexes can be used to target a gene encoding an immunogenic protein or polypeptide to a specific cell in vivo. The gene is incorporated into the target cell, expressed and the gene-encoded product is secreted and an immune response against the immunogenic protein or polypeptide is elicited. The molecular complex comprises an expressible gene encoding a desired immunogenic protein or polypeptide complexed with a carrier of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of ligands by endocytosis. An example is the asialoglycoprotein receptor of hepatocytes. The gene-binding agent is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function within a cell. The molecular complex is stable and soluble in physiological fluids and can be used to elicit an immune response against a variety of immunogens in an organism for the purpose of vaccination or for the production of antibodies.
Abstract:
Flat panel image sensor (10) is provided by combining photoconductive imaging electrodes of a vidicon with a two-dimensional array of cold cathode field emitters (14) commonly used for flat panel field emission display (FED) systems. The FED operates normally to emit electrons which are accelerated in prior art displays towards a luminescent phosphor to generate light output proportional to the cathode emission. Rather than accelerating towards a phosphor, electrons are accelerated towards a photoconductor layer (16) to replace charge removed from the layer by an incident radiation pattern directed at the photoconductor layer (16) through a layer of transparent, electrically-conducting material (17) which serves as a radiation window. The transparent, electrically-conducting layer (17) may be partitioned to reduce stray capacitance for large area sensors and the partitioned, electrically-conducting layer (17) permits a parallel readout mode of operation.
Abstract:
Molecular complexes for targeting a gene encoding an antisense polyribonucleotide to a specific cell in vivo obtaining production of the polyribonucleotide within the targeted cell, and effecting specific inhibition of the expression of cellular or noncellular genes are disclosed. An expressible gene encoding a desired antisense polyribonucleotide is complexed to a conjugate of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of ligands by endocytosis. An example is the asialoglycoprotein receptor of hepatocytes. The gene-binding agent is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function within a cell. The molecular complex is stable and soluble in physiological fluids and can be used in antisense gene therapy to selectively transfect cells in vivo or in vitro to provide for production of the antisense polyribonucleotide within the targeted cell, and inhibition of the expression of cellular or noncellular genes.
Abstract:
Molecular complexes for targeting oligonucleotides, such as antisense oligonucleotides or ribozymes, to a specific cell to block expression of a gene or genes in the cell are described. The single-stranded poly- or oligonucleotide is complexed to a conjugate of a cell-specific binding agent and a poly- or oligonucleotide-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of the complex. An example is the asialoglycoprotein receptor of hepatocytes. The poly- or oligodeoxy-nucleotide-binding agent is a compound such as a polycationic protein which stably complexes the oligonucleotide under extracellular conditions and releases it under intracellular conditions so that it can hybridize with the target RNA. The molecular complex is stable and soluble in physiological fluids and can be used to selectively introduce antisense oligonucleotides, ribozymes or other signal-stranded oligonucleotides into a cell to inhibit expression of a gene within the cell. The oligonucleotide can be directed against cellular genes (e.g., cellular oncogenes) or genes of noncellular origin (e.g., viral oncogenes, genes of an infecting pathogen).
Abstract:
The expression of polynucleotide introduced into a cell by means of a targeted complex of the polynucleotide linked to a cell-specific binding agent can be prolonged by stimulating the cell to replicate.